Discover 1,928 paid clinical trials in Plano, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,928
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
for
Small Cell Lung Cancer Metastatic or Locally Advanced,
Location: Dallas TX, Houston TX, San Antonio TX, New Orleans LA,
Sponsor: SystImmune Inc.
Sex: All
Age: 18+
Code: NCT07080242
Phase1, Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
for
Systemic Lupus Erythematosus (SLE),
Location: Allen TX, Corpus Christi TX, Atlanta GA, Tampa FL,
Sponsor: EMD Serono Research & Development Institute, Inc.
Sex: All
Age: 18 - 70+
Code: NCT07332481
Phase3, Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
for
Radiographic Axial Spondyloarthritis
Location: Fort Worth TX, Irving TX, Arlington TX, Red Oak TX,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18 - 70+
Code: NCT07133633
Phase2, Recruiting
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
for
Advanced-stage Solid Tumors
Location: Irving TX, Orlando FL
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07223125
Phase1, Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
for
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC),
Location: Dallas TX, San Antonio TX, Grand Rapids MI, Fairfax VA,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT07349537
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
for
Cancer, Cancer (Solid Tumors)
Location: Dallas TX, Huntersville NC, Fairfax VA
Sponsor: Conjupro Biotherapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07317505
Phase1, Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)